Caplin Point Laboratories
- Company typePublic
- Founded1990
- HeadquartersChennai, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Caplin Point Laboratories firmographics
Firmographics- Name
- Caplin Point Laboratories
- Legal name
- Caplin Point Laboratories Limited
- Website
- https://caplinpoint.net
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Caplin Point Laboratories industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Ophthalmic Goods Merchant Wholesalers (423460)
- SIC
- Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
- akta.pro primary industry
- Sterile Injectable Generics (HLAIABAC)
- akta.pro secondary industries
- Ophthalmic & Otic Generics (HLAIABAF), Generic Hospital & Institutional Products (HLAIABAL), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
Keywords
Where Caplin Point Laboratories is headquartered
LocationHeadquarters
- HQ city
- Chennai
- HQ country
- India
- HQ region
- Asia
Offices7 records
Markets served
Caplin Point Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Regulated Markets (US and EU): Sales of USFDA-approved generic injectable and ophthalmic products through subsidiary Caplin Steriles. Contributing 18% of total revenue in FY25. Products include complex injectables, infusion bags, and ophthalmic solutions.
- Generics and Branded Generics - LATAM and Francophone Africa: Dominant revenue contributor at 82% of FY25 sales. Products include majority under WHO essential list across 36 therapy areas. 4000+ product registrations with 900+ products in pipeline. Focus on psychiatric, neuropsychiatric, and oncology segments.
- Manufacturing and Export: 73% of exports manufactured in-house (60% within India, 13% outsourced within India), 27% from China through 10 partners. Supplies to global markets including regulated and emerging markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Generic Pharmaceutical Products |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Caplin Point Laboratories product offering
Product offeringCore offering
Caplin Point Laboratories manufactures and sells generic pharmaceutical products across multiple dosage forms — sterile injectables, ophthalmic solutions, oral solid dosages (OSD), and softgels. The company operates through its dominant LATAM and Francophone Africa branded generics business (82% of FY25 revenue, 4,000+ registrations across 36 therapies) and its US-regulated sterile injectables and ophthalmics business via subsidiary Caplin Steriles Limited (18% of FY25 revenue, 29+ USFDA ANDA approvals).
Product overview
Caplin Point Laboratories is a fully integrated pharmaceutical company organized around distinct product portfolios and subsidiaries. The company operates through its main holding structure with two key subsidiaries: Caplin Steriles Limited (CSL) for sterile injectable and ophthalmic products targeting regulated markets including the US with 29+ USFDA approvals, and Caplin One Labs Limited (COL) for oncology injectable products with dedicated manufacturing at Kakkalur. The company's primary revenue generator is its Generics and Branded Generics division for Latin America and Francophone Africa (82% of FY25 revenue, 4000+ registrations, 900+ pipeline products across 36 therapies), while its US Injectables and Ophthalmics business (18% of FY25 revenue) represents the growth platform. The company also manufactures Oral Solid Dosage forms and Softgel products at its Puducherry facility. Manufacturing is conducted in-house (60% of exports) in India and through partners in China (27% of exports).
Differentiator
Problem solved
Functional benefit
Brands
- Caplin Steriles: Subsidiary focused on injectable and ophthalmic products for regulated markets including US
- Caplin One Labs
- Caplin Point Meenakshi CSR Trust
Products and services
- Generic Injectable Products (US Regulated Market) USFDA-approved generic sterile injectable products manufactured by subsidiary Caplin Steriles Limited at the Gummidipoondi facility. Includes complex injectables, Ready-to-Use (RTU) infusion bags, and oncology injectables sold to US hospitals, healthcare institutions, and pharmacies.
- Generic Ophthalmic Solutions (US Regulated Market) USFDA-approved generic ophthalmic solutions including complex emulsion and suspension products. Indicated for ocular inflammation, glaucoma, and ocular surgery indications. Manufactured by Caplin Steriles at Gummidipoondi facility.
- Generic and Branded Generic Pharmaceuticals - LATAM and Francophone Africa Generic and branded generic pharmaceutical products including majority under WHO essential list. Covers psychiatric, neuropsychiatric, and oncology therapy areas across 36 therapy segments. Distributed via channel partners across Guatemala, Nicaragua, Honduras, El Salvador, Ecuador, Colombia, Chile, Mexico, and Francophone Africa.
- Oral Solid Dosage (OSD) Products Oral solid dosage formulations including tablets and capsules. Manufactured at the Puducherry facility (originally established for ointments, creams and external applications in 1990, expanded for OSD with 1994 IPO proceeds).
- Softgel Products Softgel pharmaceutical formulations manufactured at the INVIMA-Colombia approved Puducherry facility. Supports the LATAM expansion strategy through differentiated dosage form offerings.
- Oncology Injectable Products Oncology and complex injectable products manufactured by subsidiary Caplin One Labs Limited at a dedicated oncology facility in Kakkalur. Portfolio expanded through acquisition of 10 approved ANDAs from a multinational generic manufacturer.
- Methylprednisolone Acetate Injectable Suspension USP USFDA-approved generic corticosteroid injectable suspension indicated for anti-inflammatory and immunosuppressive therapy. Generic equivalent of DEPO-MEDROL by Pfizer Inc. Sold to US hospitals and healthcare institutions.
- Difluprednate Ophthalmic Emulsion 0.05% USFDA-approved first-cycle complex ophthalmic emulsion indicated for inflammation and pain associated with ocular surgery and endogenous anterior uveitis. Generic equivalent of DUREZOL from Sandoz Inc.
- Foscarnet Sodium Injection USFDA-approved antiviral injectable for treatment of CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. Generic equivalent of Foscavir from Clinigen Healthcare.
- Calcium Gluconate Injection USP USFDA-approved injectable indicated for treatment of acute symptomatic hypocalcemia in pediatric and adult patients. Generic equivalent of Fresenius Kabi USA's reference listed drug.
Quantifiable outcome
- 19.57% year-on-year net profit growth to Rs 641.24 crore for FY26
- +3 more outcomes
Companies that use Caplin Point Laboratories
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Caplin Point Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Caplin Point Laboratories partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Multinational Generic Manufacturer (ANDA Seller)coreAcquisition of 10 approved ANDAs for injectable and ophthalmic products from a leading multinational generic manufacturer. Addressable market of $473.2 million for the 12-month period ending August 2025. Portfolio includes select oncology injectables.
- China Manufacturing Partnerscore10 manufacturing partners in China producing 27% of total exports. Partners provide cost-efficient manufacturing capabilities and supply chain resilience for global pharmaceutical distribution.
- ARGUS Salud Pharma LLPminorSubsidiary/associate entity for pharmaceutical operations in certain markets.
Scale indicators21 records
Recent moves7 records
Expansion highlights6 records
Caplin Point Laboratories competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: Indian generic pharmaceutical manufacturer with significant sterile injectable and ophthalmic presence in the US, alongside broad emerging market operations. Direct competitor to Caplin Steriles in the US ANDA injectable space and overlapping geographic footprint in emerging markets.
- Gland Pharma: India-based sterile injectable manufacturer focused on the US market with extensive ANDA portfolio. Closest comparable to Caplin Steriles given the shared focus on complex injectables, RTU bags, and ophthalmic generics with USFDA-approved manufacturing facilities.
- Hikma Pharmaceuticals: Specialty generic injectable manufacturer serving the US, MENA, and emerging markets with comparable product portfolio in hospital injectables. Direct competitor in the US injectable generics market and overlapping emerging market presence in Middle East and Africa.
Broad incumbents
- Dr. Reddy's Laboratories: Diversified Indian pharmaceutical major with established US sterile injectables, biosimilars, and emerging market operations. Broader portfolio than Caplin but overlapping in US injectable generics and select emerging market therapeutic categories.
- Lupin Limited: Indian pharmaceutical major with US generics, complex injectables, and emerging market businesses. Comparable in US ANDA portfolio complexity and emerging market distribution footprint, though with broader therapeutic diversification.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company with extensive US generics, specialty, and emerging market operations. Overlaps with Caplin in sterile injectables and ophthalmic generics at the US market level, though with substantially broader portfolio and scale.
- Hospira (Pfizer Injectables): Largest US generic sterile injectables manufacturer and the originator/reference listed drug company for many of Caplin's ANDA targets (e.g., Sodium Phosphates, Calcium Gluconate). Sets the competitive benchmark and price reference for the markets Caplin is entering.
- Cipla Limited: Major Indian pharmaceutical company with strong emerging market presence in Africa and LATAM, plus US generics business. Comparable geographic overlap in Francophone Africa and respiratory/oncology therapy areas, though with a more diversified API and formulation mix.
- Fresenius Kabi: Global specialty/generic injectable, infusion, and clinical nutrition company. Reference listed drug manufacturer for some of Caplin's ANDA targets (e.g., Calcium Gluconate) and a major institutional competitor in the US hospital injectable market.
Regional players
- Zydus Lifesciences (Cadila): Indian pharmaceutical company with US generics, biosimilars, and emerging market operations, including specialty injectables. Comparable in US injectable pipeline and India-based manufacturing footprint, with overlapping geographic priorities in Asia and Africa.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Caplin Point Laboratories compliance and trust
Trust signalCompliance5 records
Caplin Point Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Caplin Point Laboratories leadership team
Management profileNumber of profiles
Profiles6 records
Caplin Point Laboratories subsidiaries and ownership
Company hierarchySubsidiaries6 records
Caplin Point Laboratories funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Caplin Point Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Caplin Point Laboratories
What does Caplin Point Laboratories do?
Caplin Point Laboratories manufactures and sells generic pharmaceutical products across multiple dosage forms — sterile injectables, ophthalmic solutions, oral solid dosages (OSD), and softgels. The company operates through its dominant LATAM and Francophone Africa branded generics business (82% of FY25 revenue, 4,000+ registrations across 36 therapies) and its US-regulated sterile injectables and ophthalmics business via subsidiary Caplin Steriles Limited (18% of FY25 revenue, 29+ USFDA ANDA approvals).
Is Caplin Point Laboratories a public or private company?
Caplin Point Laboratories is a public company. It is classified as public and is currently operating.
When was Caplin Point Laboratories founded?
Caplin Point Laboratories was founded in 1990. It employs 1,001 to 5,000 people.
Where is Caplin Point Laboratories based?
Caplin Point Laboratories is headquartered in Chennai, India, in the Asia region.
How does Caplin Point Laboratories make money?
Three revenue lines are on record. Regulated Markets (US and EU) is the primary driver. The others are generics and Branded Generics - LATAM and Francophone Africa and manufacturing and Export.
Who are Caplin Point Laboratories's main competitors?
Direct peers on record are Aurobindo Pharma, Gland Pharma and Hikma Pharmaceuticals. Broad incumbents are Dr. Reddy's Laboratories, Lupin Limited, Sun Pharmaceutical Industries, Hospira (Pfizer Injectables), Cipla Limited and Fresenius Kabi. Zydus Lifesciences (Cadila) is listed as a regional player.
Does Caplin Point Laboratories have an API?
No public API is recorded for Caplin Point Laboratories.
What industry is Caplin Point Laboratories in?
Caplin Point Laboratories's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAC, Sterile Injectable Generics, with a secondary code of HLAIABAF, Ophthalmic & Otic Generics. Its NAICS code is 325412 and its SIC code is 2834.